DK1610613T3 - Topiske anthelmintiske veterinære formuleringer - Google Patents
Topiske anthelmintiske veterinære formuleringer Download PDFInfo
- Publication number
- DK1610613T3 DK1610613T3 DK04758886.8T DK04758886T DK1610613T3 DK 1610613 T3 DK1610613 T3 DK 1610613T3 DK 04758886 T DK04758886 T DK 04758886T DK 1610613 T3 DK1610613 T3 DK 1610613T3
- Authority
- DK
- Denmark
- Prior art keywords
- acid
- topical formulation
- sodium
- solvent
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Topisk formulering omfattende a) en farmaceutisk aktiv kombination bestående af eprinomectin og mindst én forbindelse valgt fra gruppen bestående af praziquantel, morantel og pyrantel; b) fortykningsmiddel valgt fra povidon, maltodextrin, polydextrat, dextrater, carboxypolymethylen, polyethylenglycoler og celluloser, såsom hydro xylpropylcelluloser; c) ikke-vandigt opløsningsmiddel eller opløsningsmiddelblanding valgt fra gruppen bestående af isopropanol, polyethylenglycol, Cs-Cio capryl-/caprintriglycerider, benzylalkohol, glycofurol, N,N-dimethylacetamid, dimethylisosorbid, diethylenglycolmonoethylether, og alkoholyse/esteri-fikationsprodukt af abrikoskerneolie og PEG 300; og d) eventuelt, en antioxidant, et farvestof, en penetratinsforstærker, chelateringsmiddel, en surgøringsstabilisator, et opakiseringsmiddel, et konserveringsmiddel og/eller en krystallisationsinhibitor hvor den farmaceutisk aktive kombination opløses i det ikke-vandige opløsningsmiddel og når det ikke-vandige opløsningsmiddel er en opløsningsmiddelblanding, indeholder blandingen ikke et pyrrolidonopløsningsmiddel.
2. Topisk formulering ifølge krav 1, der indeholder en antioxidant,
3. Topisk formulering ifølge krav 1, som er en pour-on/formulering.
4. Topisk formulering ifølge krav 1, som er en spot-on-formulering.
5. Topisk formulering ifølge et hvilket som helst af de foregående krav, hvor formuleringen ikke indeholder nogen yderligere farmaceutiske aktive stoffer.
6. Topisk formulering ifølge et hvilket som helst af de foregående krav, hvor antioxidanten er valgt fra butyleret hydroxytoluen, butyleret hydroxylanisol, alfatocopherol, ascorbinsyre, ascorbylpalmitat, fumarsyre, æblesyre, citronsyre, natriumascorbat, natriummetabisulfat, monothioglycerol og n-propylgallat.
7. Topisk formulering ifølge et hvilket som helst af de foregående krav, hvor fortykningsmidlet er povidon og opløsningsmidlet er valgt fra gruppen bestående af benzylalkohol og propylenglycol.
8. Topisk formulering ifølge et hvilket som helst af de foregående krav, hvor antioxidanten er butyleret hydroxytoluen.
9. Topisk formulering ifølge et hvilket som helst af de foregående krav, hvor den makrocycliske lacton er eprinomectin og den anden forbindelse er praziquantel.
10. Topisk formulering ifølge et hvilket som helst af de foregående krav, hvor, — antioxidanten er valgt fra gruppen bestående af alfatocopherol, ascorbinsyre, ascorbylpalmitat, fumarsyre, æblesyre, natriumascorbat, natriummetabisulfat, n-propylgallat, butyleret hydroxyanisol, butyleret hydroxytoluen, monothioglycerol; — farvestoffet er farve, en aluminiumlak, karamel, og farvestof baseret på jernoxid; — konserveringsmidlet er en forbindelse valgt fra gruppen bestående af benzalkoniumchlorid, benzethoniumchlorid, benzoesyre, benzylalkohol, hronopol, butylparaben, centrimid, chlorhexidin, chlorbutanol, chlorcresol, cresol, ethylparaben, imidurea, methylparaben, propylparaben, phenol, phenoxyethanol, phenylethyl, alkohol, phenylmercuriacetat, phenylmercurborat, phenylmercurnitrat, kaliumsorbat, natriumbenzoat, natriumpropionat, sorbinsyre, og thimerosal.
11. Topisk formulering ifølge krav 4 yderligere omfattende en krystallisationsinhibitor valgt fra gruppen bestående af et anionisk overfladebehandlingsmiddel, et kationisk overfladebehandlingsmiddel, et ikke-ionisk overfladebehandlingsmiddel, et aminsalt, et amfotert overfladebehandlingsmiddel, polyvinylpyrrolidon, polyvinylalkoholer, copolymerer af vinylacetat og vinylpyrrolidon, polyethylenglycoler, benzylalkohol, mannitol, glycerol, polyvidon, sorbitol, polyoxyethylenerede sorbitanestere; lecithin, carboxymethylcellulose, og acrylderivater, eller en blanding af disse krystallisationsinhibitorer.
12. Topisk formulering ifølge krav 11, hvor - det anioniske overfladebehandlingsmiddel er alkaliske stearater, batriumabietat; alkylsulfater; natriumdodecylbenzensulfonat, natriumdioctylsulphosuccinat; og fedtsyrer; - det kationiske overfladebehandlingsmiddel er vand-opløselige kvaternære ammoniumsalte med formel N+R'R"R' "R" " Y" i hvilket R-radikalerne uafhængigt er carbonhydridradikaler, eventuelt hydroxylerede, og Y' er en anion af en stærk syre; - aminsaltet er et aminsalt af N+R'R"R' " i hvilket radikalerne R uafhængigt eventuelt er hydroxylerede carbonhydridradikaler; - det an-ioniske overfladebehandlingsmiddel er eventuelt polyoxyethylenerede sorbitanestere, polyoxyethylenerede alkylethere; polyethylenglycolstearat, polyoxyethylenerede derivater af ricinusolie, polyglycerolestere, polyoxyethylenerede fedtalkoholer, polyoxyethylenerede fedtsyrer, copolymerer af ethylenoxid og propylenoxid; og - det amfotere overfladebehandlingsmiddel er en lauryl-substitueret betainforbindelse.
13. Topisk formulering ifølge krav 11, hvor krystallisationsinhibitoren er et krystallisationsinhibitorsystem omfattende et polymer-filmdannende middel og et overfladebehandlingsmiddel.
14. Topisk formulering ifølge krav 11, hvor polymer-film-formningsmidlet er polyvinylpyrrolidon, polyvinylalkoholer, eller en copolymer af vinylacetat og polyvinylpyrrolidon og overfladebehandlingsmidlet er et ikke-ionisk overfladebehandlingsmiddel.
15. Topisk formulering ifølge krav 11, hvor krystallisationsinhibitorsystemet er en blanding af polyvinylpyrrolidon og polyoxethylen (20) sorbitanmono-oleat.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46062703P | 2003-04-04 | 2003-04-04 | |
PCT/US2004/010425 WO2004089239A2 (en) | 2003-04-04 | 2004-04-05 | Topical anthelmintic veterinary formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1610613T3 true DK1610613T3 (da) | 2017-02-27 |
Family
ID=33159788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04758886.8T DK1610613T3 (da) | 2003-04-04 | 2004-04-05 | Topiske anthelmintiske veterinære formuleringer |
Country Status (17)
Country | Link |
---|---|
US (1) | US6991801B2 (da) |
EP (1) | EP1610613B1 (da) |
JP (1) | JP2006522154A (da) |
AU (2) | AU2004228041B2 (da) |
BR (1) | BRPI0409185B1 (da) |
CA (1) | CA2521268C (da) |
CY (1) | CY1120462T1 (da) |
DK (1) | DK1610613T3 (da) |
ES (1) | ES2620413T3 (da) |
HU (1) | HUE032009T2 (da) |
LT (1) | LT1610613T (da) |
MX (1) | MXPA05010659A (da) |
NZ (1) | NZ542955A (da) |
PL (1) | PL1610613T3 (da) |
PT (1) | PT1610613T (da) |
WO (1) | WO2004089239A2 (da) |
ZA (1) | ZA200508264B (da) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10358525A1 (de) * | 2003-12-13 | 2005-07-07 | Bayer Healthcare Ag | Endoparasitizide Mittel zur topischen Applikation |
KR100595446B1 (ko) * | 2004-01-19 | 2006-07-03 | 삼성전자주식회사 | 디스플레이장치 |
US7666444B2 (en) | 2004-02-02 | 2010-02-23 | Wyeth | Antiparasitic composition |
AU2005284422A1 (en) * | 2004-09-16 | 2006-03-23 | Bayer Healthcare Ag | Dermally applicable formulations for treating skin diseases in animals |
CN101048139A (zh) * | 2004-10-28 | 2007-10-03 | 艾德克斯实验室公司 | 药物活性化合物的控释组合物 |
DE102004053964A1 (de) * | 2004-11-09 | 2006-05-11 | Bayer Healthcare Ag | Mittel gegen Demodikose |
EP1824474A1 (en) * | 2004-12-10 | 2007-08-29 | Bayer HealthCare AG | Anthelmintic composition |
DE102005011779A1 (de) * | 2005-03-11 | 2006-09-14 | Bayer Healthcare Ag | Endoparasitizide Mittel |
US20060293260A1 (en) * | 2005-05-24 | 2006-12-28 | Wyeth | Useful high load concentrate compositions for control of ecto-and endo-parasites |
CA2622002A1 (en) * | 2005-09-26 | 2007-04-05 | Piedmont Pharmaceuticals Llc | Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear |
CA2622001A1 (en) * | 2005-09-26 | 2007-04-05 | Piedmont Pharmaceuticals Llc | Methods for treatment and prevention of otitis media using chemical penetration enhancers to facilitate transmembrane drug delivery into the middle ear |
US7754679B2 (en) | 2005-11-16 | 2010-07-13 | Idexx Laboratories, Inc. | Pharmaceutical compositions for the administration of aptamers |
US8114440B2 (en) | 2005-11-16 | 2012-02-14 | Idexx Laboratories Inc. | Pharmaceutical compositions for the administration of aptamers |
US7700614B2 (en) * | 2005-12-14 | 2010-04-20 | Abbott Laboratories | One pot synthesis of tetrazole derivatives of rapamycin |
NZ548931A (en) * | 2006-05-15 | 2008-03-28 | Wyeth Corp | Stabilised formulation of moxidectin |
HUE052378T2 (hu) | 2006-09-01 | 2021-04-28 | Fmc Corp | Lokális topikális adagolású, indoxacarb tartalmú formulációk |
US8828960B2 (en) | 2007-07-17 | 2014-09-09 | Idexx Laboratories, Inc. | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
TW200924647A (en) * | 2007-08-30 | 2009-06-16 | Schering Plough Ltd | Local topical administration formulations containing fipronil |
FR2922108A1 (fr) * | 2007-10-11 | 2009-04-17 | Virbac Sa | Utilisation d'un derive de 1-n-(halo-3-pyridylmethyle)-n-methylamino-1-alkylamino -2- nitroethylene pour la preparation d'une composition pharmaceutique veterinaire pour lutter contre les puces |
WO2009070687A1 (en) * | 2007-11-26 | 2009-06-04 | Merial Limited | Solvent systems for pour-on formulations for combating parasites |
FR2925337B1 (fr) * | 2007-12-21 | 2010-01-15 | Virbac | Composition pharmaceutique contenant un derive de n-phenylpyrazole et du glycofurol, utilisation pour la preparation d'un medicament veterinaire topique pour lutter contre les puces |
BRPI0802255A2 (pt) * | 2008-06-17 | 2010-03-16 | Sespo Ind E Com Ltda | composição de uso tópico para controle de ectoparasitos em cães e gatos |
WO2010106325A2 (en) | 2009-03-18 | 2010-09-23 | Omnipharm Limited | Parasiticidal formulation |
GB0905365D0 (en) | 2009-03-27 | 2009-05-13 | Norbrook Lab Ltd | A topical parasiticide composition |
US8313752B2 (en) * | 2009-04-14 | 2012-11-20 | Merial Limited | Macrocyclic lactone combination compositions, vaccines and methods for producing same |
AU2010330844B2 (en) * | 2009-12-17 | 2014-11-27 | Boehringer Ingelheim Animal Health USA Inc. | Compositions comprising macrocyclic lactone compounds and spirodioxepinoindoles |
UA108641C2 (uk) * | 2010-04-02 | 2015-05-25 | Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування | |
AU2015202084B2 (en) * | 2010-04-02 | 2016-07-28 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
AU2016247183B2 (en) * | 2010-04-02 | 2018-03-29 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising multiple active agents, methods and uses thereof |
PT2658541T (pt) * | 2010-12-27 | 2022-03-11 | Intervet Int Bv | Formulação de isoxazolina localizada tópica compreendendo glicofurol |
CN102221293B (zh) * | 2011-06-08 | 2013-05-08 | 大连理工大学 | 一种熔炼坩埚用涂层的制备方法 |
US20120329832A1 (en) * | 2011-06-27 | 2012-12-27 | Jean Delaveau | Novel Insect-Repellent Coumarin Derivatives, Syntheses, and Methods of Use |
DK2755473T3 (da) | 2011-09-12 | 2019-03-11 | Merial Inc | Paraciticide sammensætninger omfattende et isoxazolin-aktivtstof, fremgangsmåder og anvendelser deraf |
EP2934522B1 (en) * | 2012-12-18 | 2018-08-15 | Donaghys Limited | Transdermal parasiticidal formulations |
US8993613B2 (en) | 2013-04-17 | 2015-03-31 | The Hartz Mountain Corporation | Ectoparasiticidal formulations |
NZ701697A (en) | 2014-03-24 | 2016-05-27 | Donaghys Ltd | Stable veterinary anthelmintic formulations |
AR104691A1 (es) * | 2016-05-18 | 2017-08-09 | Labyes De Uruguay S A | Composición veterinaria de imidacloprid, moxidectina y praziquantel de administración tópica cutánea (spot on) para tratamiento y prevención de las ecto y endoparasitosis que afectan a los perros |
GB2552952B (en) * | 2016-08-12 | 2020-03-04 | Norbrook Lab Ltd | Moxidectin topical liquid formulations |
WO2019054967A2 (en) * | 2017-03-15 | 2019-03-21 | Verano Ilac Sanayi Ve Ticaret Anonim Sirketi | VETERINARY COMPOSITION TO BE POURED COMPRISING EPRINOMECTIN |
EP3595441B1 (en) | 2017-03-17 | 2023-08-02 | KRKA, d.d., Novo mesto | Stable topical veterinary composition |
WO2019025561A1 (en) * | 2017-08-03 | 2019-02-07 | Universität Regensburg | FUEL FROM RENEWABLE RESOURCES |
CN111386112A (zh) * | 2017-11-23 | 2020-07-07 | 法国诗华大药厂 | 用于治疗寄生虫感染的含有莫昔克丁的组合物 |
EP3749096A1 (en) | 2018-02-08 | 2020-12-16 | Boehringer Ingelheim Animal Health USA Inc. | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof |
KR102188378B1 (ko) * | 2018-11-02 | 2020-12-08 | 녹십자수의약품(주) | 셀라멕틴을 포함하는 구충제 조성물 |
CN110835471B (zh) * | 2019-11-19 | 2021-06-18 | 广州市汇合彩颜料有限公司 | 一种用于研磨颜料的低挥发有机溶剂制备方法 |
US10857151B1 (en) * | 2020-02-21 | 2020-12-08 | Villya LLC | Treatment of female genital schistosomiasis |
CN113209012A (zh) * | 2021-06-04 | 2021-08-06 | 湖南伟达科技有限公司 | 一种阿维菌素透皮溶液及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57139012A (en) * | 1981-02-23 | 1982-08-27 | Sankyo Co Ltd | Anthelmintic composition |
GB2221621A (en) * | 1988-08-12 | 1990-02-14 | Merck & Co Inc | Synergistic antiparasitic combinations of avermectin and pyrantel |
US5439924A (en) * | 1991-12-23 | 1995-08-08 | Virbac, Inc. | Systemic control of parasites |
BG61064B1 (bg) * | 1993-08-12 | 1996-10-31 | Илия Илиев | Лекарствено средство за обезпаразитяване на животни |
DE4417742A1 (de) * | 1994-05-20 | 1995-11-23 | Bayer Ag | Nicht-systemische Bekämpfung von Parasiten |
AUPM969994A0 (en) * | 1994-11-28 | 1994-12-22 | Virbac S.A. | Equine anthelmintic formulations |
NZ272574A (en) * | 1995-07-14 | 1999-02-25 | Lilly Eli & Co Nz Ltd | Aqueous base suspension concentrate containing at least one ionophore antibiotic and wetting agent and/or a surfactant and xanthan gum optionally with a suspension agent, an antifreeze agent and an antifoaming agent; drench for veterinary treatment |
US5773422A (en) * | 1996-01-29 | 1998-06-30 | Komer; Gene | Avermectin formulation |
US6413542B1 (en) | 1996-03-29 | 2002-07-02 | Merial | Direct pour-on antiparasitic skin solution and methods for treating, preventing and controlling myasis |
IE80657B1 (en) | 1996-03-29 | 1998-11-04 | Merial Sas | Insecticidal combination to control mammal fleas in particular fleas on cats and dogs |
US5958888A (en) | 1996-07-02 | 1999-09-28 | Merial, Inc. | Water miscible macrolide solutions |
CA2260143C (en) * | 1996-07-30 | 2004-07-13 | Ashmont Holdings Limited | Anthelmintic formulations |
FR2753377B1 (fr) * | 1996-09-19 | 1999-09-24 | Rhone Merieux | Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides |
US6426333B1 (en) | 1996-09-19 | 2002-07-30 | Merial | Spot-on formulations for combating parasites |
DE19654079A1 (de) * | 1996-12-23 | 1998-06-25 | Bayer Ag | Endo-ekto-parasitizide Mittel |
US6042775A (en) | 1998-01-29 | 2000-03-28 | Tm Industrial Supply, Inc. | Silver reclamation system |
US6239112B1 (en) | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
AU770879B2 (en) * | 1999-08-12 | 2004-03-04 | Eli Lilly And Company | Ectoparasiticidal aqueous suspension formulations of spinosyns |
WO2001020994A1 (en) * | 1999-09-22 | 2001-03-29 | Ashmont Holdings Limited | Sheep pour-on |
US6787342B2 (en) | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
US6340672B1 (en) * | 2000-02-16 | 2002-01-22 | Phoenix Scientific, Inc. | Parasiticidal formulation and a method of making this formulation |
US6207179B1 (en) * | 2000-05-18 | 2001-03-27 | Phoenix Scientific, Inc. | Parasiticidal formulation for animals and a method of making this formulation |
GB0108485D0 (en) * | 2001-04-04 | 2001-05-23 | Pfizer Ltd | Combination therapy |
HUP0500984A3 (en) * | 2001-09-17 | 2007-02-28 | Lilly Co Eli | Synergetic pesticidal formulations |
US20040234580A1 (en) * | 2001-10-05 | 2004-11-25 | Huber Gordon R. | Animal feeds including actives and methods of using the same |
US7001889B2 (en) * | 2002-06-21 | 2006-02-21 | Merial Limited | Anthelmintic oral homogeneous veterinary pastes |
US20040037869A1 (en) * | 2002-08-16 | 2004-02-26 | Douglas Cleverly | Non-animal product containing veterinary formulations |
-
2004
- 2004-04-05 MX MXPA05010659A patent/MXPA05010659A/es active IP Right Grant
- 2004-04-05 US US10/818,313 patent/US6991801B2/en not_active Expired - Lifetime
- 2004-04-05 BR BRPI0409185-0A patent/BRPI0409185B1/pt active IP Right Grant
- 2004-04-05 LT LTEP04758886.8T patent/LT1610613T/lt unknown
- 2004-04-05 HU HUE04758886A patent/HUE032009T2/en unknown
- 2004-04-05 JP JP2006509704A patent/JP2006522154A/ja active Pending
- 2004-04-05 PL PL04758886T patent/PL1610613T3/pl unknown
- 2004-04-05 CA CA2521268A patent/CA2521268C/en not_active Expired - Lifetime
- 2004-04-05 EP EP04758886.8A patent/EP1610613B1/en not_active Expired - Lifetime
- 2004-04-05 PT PT47588868T patent/PT1610613T/pt unknown
- 2004-04-05 ES ES04758886.8T patent/ES2620413T3/es not_active Expired - Lifetime
- 2004-04-05 DK DK04758886.8T patent/DK1610613T3/da active
- 2004-04-05 NZ NZ542955A patent/NZ542955A/en unknown
- 2004-04-05 AU AU2004228041A patent/AU2004228041B2/en not_active Expired
- 2004-04-05 WO PCT/US2004/010425 patent/WO2004089239A2/en active Application Filing
-
2005
- 2005-10-12 ZA ZA200508264A patent/ZA200508264B/en unknown
-
2009
- 2009-08-24 AU AU2009212762A patent/AU2009212762A1/en not_active Withdrawn
-
2017
- 2017-03-02 CY CY20171100273T patent/CY1120462T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0409185A (pt) | 2006-04-11 |
HUE032009T2 (en) | 2017-09-28 |
NZ542955A (en) | 2008-07-31 |
CA2521268A1 (en) | 2004-10-21 |
MXPA05010659A (es) | 2005-12-12 |
LT1610613T (lt) | 2017-03-27 |
CA2521268C (en) | 2012-10-16 |
PT1610613T (pt) | 2017-03-07 |
BRPI0409185B1 (pt) | 2018-05-15 |
EP1610613A4 (en) | 2012-05-02 |
US6991801B2 (en) | 2006-01-31 |
AU2004228041B2 (en) | 2009-06-04 |
US20040198676A1 (en) | 2004-10-07 |
PL1610613T3 (pl) | 2017-06-30 |
WO2004089239A2 (en) | 2004-10-21 |
AU2004228041A1 (en) | 2004-10-21 |
JP2006522154A (ja) | 2006-09-28 |
ES2620413T3 (es) | 2017-06-28 |
WO2004089239A3 (en) | 2004-11-25 |
AU2009212762A1 (en) | 2009-09-17 |
EP1610613A2 (en) | 2006-01-04 |
ZA200508264B (en) | 2007-03-28 |
EP1610613B1 (en) | 2016-12-28 |
CY1120462T1 (el) | 2019-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1610613T3 (da) | Topiske anthelmintiske veterinære formuleringer | |
EP1534072B1 (en) | Anthelmintic oral homogeneous veterinary pastes | |
DK1957040T3 (da) | Ikke-vandige benzimidazolsammensætninger | |
AU2008282388A1 (en) | Endoparasiticidal topical compositions | |
EP1551390B1 (en) | Formulation comprising avermectins / milbemycins and levamisole in a pyrrolidone solvent | |
US7638545B1 (en) | Anthelmintic composition | |
ES2846820T3 (es) | Composición de lactonas macrocíclicas, levamisol, un aminoazúcar y un agente antiparasitario adicional | |
EP1940396B1 (en) | Anthelmintic formulations | |
AU2003238245B2 (en) | Anthelmintic oral homogeneous veterinary pastes | |
AU2013204176B2 (en) | Stable veterinary combination formulations of macrocyclic lactones and imidazothiazoles | |
US8067382B2 (en) | Anthelmintic composition | |
NZ535644A (en) | Anthelmintic formulations | |
NZ530286A (en) | Anthelmintic formulations containing triclabendazole |